1
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry L Brielmann, James William Darrow, Stéphane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Louis Elliott, Marlys Hammond: Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines. Pfizer, Neurogen Corporation, Ladas & Parry, May 20, 2003: US06566367 (57 worldwide citation)

Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treat ...


2
Bruce A Dressman, James E Fritz, Marlys Hammond, William J Hornback, Stephen W Kaldor, Vincent J Kalish, John E Munroe, Siegfried H Reich, John H Tatlock, Timothy A Shepherd, Michael J Rodriguez: HIV protease inhibitors. Agouron Pharmaceuticals, Finnegan Henderson Farabow Garrett & Dunner, January 16, 1996: US05484926 (57 worldwide citation)

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral ...


3

4
Bruce A Dressman, James E Fritz, Marlys Hammond, William J Hornback, Stephen W Kaldor, Vincent J Kalish, John E Munroe, Siegfried Heinz Reich, John H Tatlock, Timothy A Shepherd, Michael J Rodriguez: HIV protease inhibtors. Agouron Pharmaceuticals, Finnegan Henderson Farabow Garrett & Dunner L, October 27, 1998: US05827891 (15 worldwide citation)

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral ...


5
James E Fritz, Marlys Hammond, Stephen W Kaldor: Inhibitors of HIV protease. Eli Lilly and Company, Janet T McClain, Gerald V Dahling, July 18, 1995: US05434265 (12 worldwide citation)

The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating HIV infection.


6
James E Fritz, Marlys Hammond, Stephen W Kaldor: Intermediates for preparing HIV protease inhibitors. Eli Lilly and Company, Janet T McClain, May 7, 1996: US05514802 (11 worldwide citation)

The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.


7
Stephen W Kaldor, Marlys Hammond: Retroviral protease inhibitors. Eli Lilly and Company, Janet T McClain, April 16, 1996: US05508407 (10 worldwide citation)

The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of their use.


8
Richard L Elliott, Kimberly O Cameron, Marlys Hammond: Tetraazabenzo[e]azulene derivatives and analogs thereof. Pfizer, Gregg C Benson, Robert M Kennedy, September 4, 2007: US07265104 (9 worldwide citation)

This invention relates to CCK-A agonists of Formula (I) wherein R1-R4, A, B, X, D, E and G are as defined in the specificiation, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in trea ...


9

10
Marlys Hammond, Stephen W Kaldor: Anti-picornaviral agents. Eli Lilly and Company, Paul R Cantrell, May 7, 1996: US05514778 (8 worldwide citation)

The present invention provides a group of novel compounds that inhibit the proteolytic activity of 3C proteases which are found in picornaviruses, particularly rhinoviruses. In picornaviruses the RNA genome is translated into a single large viral polyprotein precursor. The precursor demonstrates aut ...



Click the thumbnails below to visualize the patent trend.